A randomized, double-blind, placebo-controlled prospective clinical study (Zhu et al., 2018) observed the efficacy and safety of Fuzheng Zhiai herbs combined with EGFR-TKIs targeted drugs in the treatment of advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.